Genus (LON:GNS) Receives “Buy” Rating from Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of Genus (LON:GNSFree Report) in a research note issued to investors on Thursday morning, MarketBeat reports. They currently have a GBX 3,350 target price on the stock.

A number of other analysts also recently weighed in on GNS. Deutsche Bank Aktiengesellschaft increased their target price on shares of Genus from GBX 3,100 to GBX 3,300 and gave the company a “buy” rating in a research report on Friday, January 16th. Shore Capital reissued a “buy” rating and set a GBX 3,000 target price on shares of Genus in a research note on Friday, January 16th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of GBX 3,216.67.

Check Out Our Latest Report on GNS

Genus Trading Up 2.8%

Shares of GNS stock opened at GBX 3,145.43 on Thursday. Genus has a 1-year low of GBX 1,548 and a 1-year high of GBX 3,228.80. The company has a current ratio of 1.80, a quick ratio of 1.08 and a debt-to-equity ratio of 53.12. The stock has a market cap of £2.09 billion, a price-to-earnings ratio of 108.84, a PEG ratio of 2.87 and a beta of 0.37. The stock has a 50-day moving average of GBX 2,686.97 and a 200-day moving average of GBX 2,581.68.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.

Featured Stories

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.